-
Something wrong with this record ?
Thresholds for surfactant use in preterm neonates: a network meta-analysis
A. Branagan, I. Yu, K. Gurusamy, J. Miletin
Language English Country England, Great Britain
Document type Systematic Review, Meta-Analysis, Journal Article
NLK
ProQuest Central
from 1997-01-01 to 6 months ago
Health & Medicine (ProQuest)
from 1997-01-01 to 6 months ago
- MeSH
- Bayes Theorem MeSH
- Humans MeSH
- Infant, Premature MeSH
- Infant, Newborn MeSH
- Pulmonary Surfactants * therapeutic use MeSH
- Surface-Active Agents MeSH
- Network Meta-Analysis MeSH
- Respiratory Distress Syndrome, Newborn * drug therapy prevention & control MeSH
- Pregnancy MeSH
- Check Tag
- Humans MeSH
- Infant, Newborn MeSH
- Pregnancy MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Meta-Analysis MeSH
- Systematic Review MeSH
OBJECTIVE: To perform a network meta-analysis of randomised controlled trials of different surfactant treatment strategies for respiratory distress syndrome (RDS) to assess if a certain fraction of inspired oxygen (FiO2) is optimal for selective surfactant therapy. DESIGN: Systematic review and network meta-analysis using Bayesian analysis of randomised trials of prophylactic versus selective surfactant for RDS. SETTING: Cochrane Central Register of Controlled Trials, MEDLINE, Embase and Science Citation Index Expanded. PATIENTS: Randomised trials including infants under 32 weeks of gestational age. INTERVENTIONS: Intratracheal surfactant, irrespective of type or dose. MAIN OUTCOME MEASURES: Our primary outcome was neonatal mortality, compared between groups treated with selective surfactant therapy at different thresholds of FiO2. Secondary outcomes included respiratory morbidity and major complications of prematurity. RESULTS: Of 4643 identified references, 14 studies involving 5298 participants were included. We found no statistically significant differences between 30%, 40% and 50% FiO2 thresholds. A sensitivity analysis of infants treated in the era of high antenatal steroid use and nasal continuous positive airway pressure as initial mode of respiratory support showed no difference in mortality, RDS or intraventricular haemorrhage alone but suggested an increase in the combined outcome of major morbidities in the 60% threshold. CONCLUSION: Our results do not show a clear benefit of surfactant treatment at any threshold of FiO2. The 60% threshold was suggestive of increased morbidity. There was no advantage seen with prophylactic treatment. Randomised trials of different thresholds for surfactant delivery are urgently needed to guide clinicians and provide robust evidence. PROSPERO REGISTRATION NUMBER: CRD42020166620.
2nd Faculty of Medicine Motol University Hospital Prague Czech Republic
Department of Therapy 1 M Sechenov 1st Moscow State Medical University Moskva Russian Federation
Division of Surgery and Interventional Science UCL London UK
Institute for the Care of Mother and Child Prague Czech Republic
Paediatric and Newborn Medicine Coombe Women and Infants University Hospital Dublin Ireland
UCD School of Medicine University College Dublin Dublin Ireland
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23010960
- 003
- CZ-PrNML
- 005
- 20230801132728.0
- 007
- ta
- 008
- 230718s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1136/archdischild-2022-324184 $2 doi
- 035 __
- $a (PubMed)36600484
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Branagan, Aoife $u Paediatric and Newborn Medicine, Coombe Women and Infants University Hospital, Dublin, Ireland branagaa@tcd.ie $u Division of Surgery and Interventional Science, UCL, London, UK $1 https://orcid.org/0000000152205372
- 245 10
- $a Thresholds for surfactant use in preterm neonates: a network meta-analysis / $c A. Branagan, I. Yu, K. Gurusamy, J. Miletin
- 520 9_
- $a OBJECTIVE: To perform a network meta-analysis of randomised controlled trials of different surfactant treatment strategies for respiratory distress syndrome (RDS) to assess if a certain fraction of inspired oxygen (FiO2) is optimal for selective surfactant therapy. DESIGN: Systematic review and network meta-analysis using Bayesian analysis of randomised trials of prophylactic versus selective surfactant for RDS. SETTING: Cochrane Central Register of Controlled Trials, MEDLINE, Embase and Science Citation Index Expanded. PATIENTS: Randomised trials including infants under 32 weeks of gestational age. INTERVENTIONS: Intratracheal surfactant, irrespective of type or dose. MAIN OUTCOME MEASURES: Our primary outcome was neonatal mortality, compared between groups treated with selective surfactant therapy at different thresholds of FiO2. Secondary outcomes included respiratory morbidity and major complications of prematurity. RESULTS: Of 4643 identified references, 14 studies involving 5298 participants were included. We found no statistically significant differences between 30%, 40% and 50% FiO2 thresholds. A sensitivity analysis of infants treated in the era of high antenatal steroid use and nasal continuous positive airway pressure as initial mode of respiratory support showed no difference in mortality, RDS or intraventricular haemorrhage alone but suggested an increase in the combined outcome of major morbidities in the 60% threshold. CONCLUSION: Our results do not show a clear benefit of surfactant treatment at any threshold of FiO2. The 60% threshold was suggestive of increased morbidity. There was no advantage seen with prophylactic treatment. Randomised trials of different thresholds for surfactant delivery are urgently needed to guide clinicians and provide robust evidence. PROSPERO REGISTRATION NUMBER: CRD42020166620.
- 650 _2
- $a těhotenství $7 D011247
- 650 _2
- $a novorozenec $7 D007231
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a povrchově aktivní látky $7 D013501
- 650 _2
- $a síťová metaanalýza $7 D000071076
- 650 _2
- $a Bayesova věta $7 D001499
- 650 _2
- $a novorozenec nedonošený $7 D007234
- 650 12
- $a plicní surfaktanty $x terapeutické užití $7 D011663
- 650 12
- $a syndrom respirační tísně novorozenců $x farmakoterapie $x prevence a kontrola $7 D012127
- 655 _2
- $a systematický přehled $7 D000078182
- 655 _2
- $a metaanalýza $7 D017418
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Yu, Ivan $u Paediatric and Newborn Medicine, Coombe Women and Infants University Hospital, Dublin, Ireland $u Division of Surgery and Interventional Science, UCL, London, UK
- 700 1_
- $a Gurusamy, Kurinchi $u Division of Surgery and Interventional Science, UCL, London, UK $u Department of Therapy, I.M. Sechenov First Moscow State Medical University, Moskva, Russian Federation
- 700 1_
- $a Miletin, Jan $u Paediatric and Newborn Medicine, Coombe Women and Infants University Hospital, Dublin, Ireland $u UCD School of Medicine, University College Dublin, Dublin, Ireland $u Institute for the Care of Mother and Child, Prague, Czech Republic $u 2nd Faculty of Medicine, Motol University Hospital, Prague, Czech Republic $1 https://orcid.org/0000000304896054 $7 xx0071047
- 773 0_
- $w MED00004943 $t Archives of disease in childhood. Fetal and neonatal edition $x 1468-2052 $g Roč. 108, č. 4 (2023), s. 333-341
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36600484 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20230801132725 $b ABA008
- 999 __
- $a ok $b bmc $g 1963406 $s 1197225
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 108 $c 4 $d 333-341 $e 20221209 $i 1468-2052 $m Archives of disease in childhood. Fetal and neonatal edition $n Arch Dis Child Fetal Neonatal Ed $x MED00004943
- LZP __
- $a Pubmed-20230718
